Kaufman Michael J. 4
4 · Mersana Therapeutics, Inc. · Filed Jul 19, 2021
Insider Transaction Report
Form 4
Kaufman Michael J.
Chief Manufacturing Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2021-07-15+40,000→ 44,710 total - Sale
Common Stock
[F2][F3]2021-07-16$12.47/sh−5,776$72,027→ 38,934 total - Sale
Common Stock
[F2][F4]2021-07-19$12.02/sh−6,312$75,870→ 32,622 total - Exercise/Conversion
Restricted Stock Units
[F1][F5]2021-07-15−40,000→ 0 total→ Common Stock (40,000 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") listed in Table II represented a contingent right to receive one share of the Issuer's common stock upon vesting.
- [F2]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the reporting person
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $12.61, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.23, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- [F5]The RSUs vested in their entirety on July 15, 2021.
Signature
/s/ Brian DeSchuytner, as Attorney-in-Fact|2021-07-19